CD33 and acute myeloid leukemia: In addition, several anti-CSC therapies are under investigation, including the administration of all-trans retinoic acid to induce CSC terminal differentiation [56], inhibition of key CSC signalling pathways [57] or CSC ablation using antibody-drug conjugates such as CD33 in AML [58].